Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

Home-loan rivalry set to spice up as ANZ loses market share
Finance

Home-loan rivalry set to spice up as ANZ loses market share

ANZ NZ's underlying full-year profit eases higher as it eyes home-loan offering. 

NZX flat after Vital announcement
Markets

NZX flat after Vital announcement

The NZX was flat, but property stocks declined more than 1%.

Graham Skellern 10 Nov 2025
Economic hedges help ANZ NZ lift annual profit
Finance

Economic hedges help ANZ NZ lift annual profit

ANZ NZ styles its full-year results as solid as net-interest margin nudges higher.

Andy Macdonald 10 Nov 2025
PaySauce shares rise as it eyes Australia
Markets

PaySauce shares rise as it eyes Australia

Customer numbers for micro and rural payroll firm increased 9% for six months to Sept 30.